CELLDEX THERAPEUTICS INC
CLDX | NASDAQ Stock Exchange Capital MarketBusiness Summary
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Country of Incorporation
United States of America
Incorporation Date
1983-12-09
Business Sector
Pharmaceuticals & Medical Research
Company Address
53 Frontage Road, Suite 220
Get access to the below data and more business development tools by signing up for the MENA Company Data product.
- Ownership details
- Corporate structure
- Business classification
- Officers & Directors contact details
- Full company contact details
Multiply your reach by contributing your content to LSEG
LSEG contributed content reaches tens of thousands of buy and sell side professionals around the world through an integrated suite of market intelligence and transaction platforms.NEWS ON THIS COMPANY
TOP PICKS
MOST READ
MOST WATCHED
MOST POPULAR
1.
2.
3.
4.
5.
